Clinical trial
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
NCT05560659
Study timeline
Study start (actual)2023-12-14Date precision: day
Registry last updated2025-07-11
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Oligometastatic Prostate Cancerunresolved
Interventions
177Lu-PSMADRUG
Sponsors & collaborators
Peter MacCallum Cancer Centre, Australialead sponsor
Varian Medical Systemscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05560659 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.